Recently, humanized immune checkpoint animal models were developed for targeting PD-1/PD-L1 [11] and it was demonstrated that murine PD-L1 deletion and hPD-L1 replacement did not significantly affect tumor cell growth in vitro and in vivo studies [21]. Here, PDCD1 is linked to neoplasm.